Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Biogen (BIIB) and Quest Diagnostics (DGX)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cardinal Health (CAH – Research Report), Biogen (BIIB – Research Report) and Quest Diagnostics (DGX – Research Report).
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cardinal Health (CAH)
J.P. Morgan analyst Lisa Gill maintained a Hold rating on Cardinal Health yesterday and set a price target of $243.00. The company’s shares closed last Tuesday at $220.27.
According to TipRanks.com, Gill is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cardinal Health with a $250.50 average price target, a 10.8% upside from current levels. In a report issued on February 5, TipRanks – Google also downgraded the stock to Hold with a $223.00 price target.
See the top stocks recommended by analysts >>
Biogen (BIIB)
In a report released yesterday, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Biogen, with a price target of $214.00. The company’s shares closed last Tuesday at $188.99.
According to TipRanks.com, Matteis is a 5-star analyst with an average return of
Biogen has an analyst consensus of Moderate Buy, with a price target consensus of $204.45, which is a 5.3% upside from current levels. In a report issued on January 30, Oppenheimer also maintained a Buy rating on the stock with a $225.00 price target.
Quest Diagnostics (DGX)
In a report released yesterday, Patrick B Donnelly from Citi maintained a Hold rating on Quest Diagnostics, with a price target of $215.00. The company’s shares closed last Tuesday at $205.35.
According to TipRanks.com, Donnelly is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Quest Diagnostics with a $207.50 average price target.
